ClinicalTrials.gg

Program

Megestrol Acetate

Also written as “Nano-crystalline Megestrol Acetate Oral Suspension”, “Megestrol acetate concentrated suspension 125 mg/mL” and “Megestrol acetate”.

Its studies are mostly in Anorexia · Cachexia · Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis, led by 6 companies.

Furthest: phase 4, since Nov 15, 202518 company-led studies, 7 open or runningNext primary completion: Dec 31, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical77 open or runningphase 4since Nov 15, 2025Dec 25, 2024Dec 31, 2026phase 4 · NCT07243379
Bristol-Myers Squibb30 open or runningphase 4since Nov 2, 1999Nov 2, 1999none ahead
Par Health30 open or runningphase 3since Mar 11, 2008Mar 11, 2008none ahead
Keenova Therapeutics20 open or runningphase 2since Mar 11, 2008Mar 11, 2008none ahead
Rottapharm Spain20 open or runningphase 3since Jul 17, 2007Jul 17, 2007none ahead
TTY Biopharm10 open or runningphase 2since Jul 25, 2016Jul 25, 2016none ahead

Also a collaborator on its studies: quintiles-inc, covance, sfbc-anapharm and pra-health-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Nov 2, 1999.

  1. Nov 2, 1999Phase 3 study in AnorexiaBristol-Myers Squibb · NCT00002067 · United States
  2. Jul 17, 2007Rottapharm Spain's first study: phase 3 study in DementiaNew to Rottapharm SpainRottapharm Spain · NCT00503516 · 39 enrolled · Spain
  3. Jul 26, 2007Phase 2 study in Pulmonary Disease, Chronic ObstructiveRottapharm Spain · NCT00507949 · 40 enrolled · Spain
  4. Mar 11, 2008Keenova Therapeutics's first study: phase 1 study in PharmacokineticsNew to Keenova TherapeuticsKeenova Therapeutics · NCT00638079 · 24 enrolled · Canada
  5. Mar 11, 2008Par Health's first studies: 2 phase 3 studies in AnorexiaNew to Par HealthPar Health · NCT00637806, NCT00637728
  6. Mar 11, 2008Phase 2 study in HIV InfectionsKeenova Therapeutics · NCT00637572 · 63 enrolled · United States, India, South Africa
  7. Mar 11, 2008Phase 1 study in Renal InsufficiencyPar Health · NCT00637403 · 7 enrolled · United States
  8. Jul 25, 2016TTY Biopharm's first study: phase 2 study in Head and Neck NeoplasmsNew to TTY BiopharmTTY Biopharm · NCT02980653 · 105 enrolled · Taiwan
  9. Dec 25, 2024Changchun GeneScience Pharmaceutical's first study: phase 3 study in Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk FactorsNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT06772428 · 96 planned · China
  10. Feb 11, 2025No phase study in Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line TreatmentChangchun GeneScience Pharmaceutical · NCT06830018 · 76 planned · China
  11. Apr 29, 20252 phase 3 studiesChangchun GeneScience Pharmaceutical · NCT06961201, NCT06961188
  12. Aug 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungChangchun GeneScience Pharmaceutical · NCT07150663 · 134 planned · China
  13. Nov 15, 2025Phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaChangchun GeneScience Pharmaceutical · NCT07243379 · 495 planned · China
  14. Jan 4, 2026Phase 3 study in CachexiaChangchun GeneScience Pharmaceutical · NCT07356037 · 68 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaChangchun GeneScience Pharmaceutical · NCT07243379
  2. Dec 31, 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaChangchun GeneScience Pharmaceutical · NCT06961201
  3. Jun 30, 2027Primary completion: phase 3 study in CachexiaChangchun GeneScience Pharmaceutical · NCT07356037
  4. Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungChangchun GeneScience Pharmaceutical · NCT07150663

TargetBeta

PGR →read by rule
“Progesterone receptor agonist”ChEMBL 37, by rule

Other programs on PGR

ProgramCompanyFurthest phaseStudies
LevonorgestrelruleBayerphase 456
drospirenoneruleestetraphase 420
Medroxyprogesterone AcetaterulePfizerphase 411
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Utrogestanrulecalla-lily-clinical-care-ltdphase 11

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07356037Cachexia · China3Not yet recruitingChangchun GeneScience PharmaceuticalJun 30, 202768
NCT07243379Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia · China4RecruitingChangchun GeneScience PharmaceuticalDec 31, 2026495
NCT07150663Carcinoma, Non-Small-Cell Lung · China3RecruitingChangchun GeneScience PharmaceuticalJun 30, 2027134
NCT06961201Small Cell Lung Carcinoma · China3Not yet recruitingChangchun GeneScience PharmaceuticalDec 31, 202694
NCT06961188Neoplasm Metastasis · China3Not yet recruitingChangchun GeneScience PharmaceuticalJun 30, 2027174
NCT06830018Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line Treatment · China–RecruitingChangchun GeneScience PharmaceuticalJan 202676
NCT06772428Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors · China3Not yet recruitingChangchun GeneScience PharmaceuticalJun 30, 202796
NCT02980653Head and Neck Neoplasms · Taiwan2UNKNOWNTTY BiopharmAug 2017105
NCT00638079Pharmacokinetics · Canada1CompletedKeenova TherapeuticsJul 200624
NCT00637806Anorexia · United States3TerminatedPar HealthSep 20064
NCT00637728Anorexia · United States3TerminatedPar HealthSep 20065
NCT00637572HIV Infections · United States, India, South Africa2CompletedKeenova TherapeuticsJun 200563
NCT00637403Renal Insufficiency · United States1TerminatedPar HealthMay 20067
NCT00507949Pulmonary Disease, Chronic Obstructive · Spain2CompletedRottapharm SpainApr 200940
NCT00503516Dementia · Spain3TerminatedRottapharm SpainDec 200939
NCT00002345Anorexia · United States4CompletedBristol-Myers Squibb40
NCT00002300Anorexia · United States2CompletedBristol-Myers Squibb
NCT00002067Anorexia · United States3CompletedBristol-Myers Squibb

How it is read

Names in the registry

  • “Nano-crystalline Megestrol Acetate Oral Suspension”, 5 entries
  • “Megestrol acetate concentrated suspension 125 mg/mL”, 5 entries
  • “Megestrol acetate”, 5 entries
  • “Nanocrystalline Megestrol Acetate”, 2 entries
  • “Megestrol acetate concentrated suspension 110 mg/mL”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.